Zydus Lifesciences receives tentative FDA approval for Azilsartan Medoxomil Tablets
Zydus Lifesciences Limited has achieved a significant milestone with the tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil Tablets, in 40 mg and 80 mg dosages. This medication is an angiotensin II receptor blocker (ARB) specifically used for the treatment of hypertension to lower blood pressure, thereby reducing […]